Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will not sell its copycat weight-loss pill.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results